Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
IBRU+RITU
- Cancer Type
- Hematologic
- Intent
-
Palliative
- Regimen Category
-
Evidence-informed
- Funding Program
-
Exceptional Access Program iBRUtinib - For the treatment of patients with relapsed or refractory Waldenstrӧm Macroglobulinemia, in combination with rituximab, based on criteria. New Drug Funding Program Rituximab (Biosimilar IV) and Rituximab SC - In Combination with Ibrutinib for Previously Treated Waldenstrӧms Macroglobulinemia
- Drugs Used
- iBRUtinib , riTUXimab , riTUXimab (subcut)
Regimen Monograph
Apr 2025
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: July 27, 2026
